Latest news for SSY Group (OTC:LJUIF) Stock

SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

News

Intraday Update

Markets

Movers

Trading Ideas

AAON

ADYYF

AIQUY

ALPMY

AMZN

APLT

APPF

APTO

ATBPF

BXMT

CHDN

CHTR

CLHRF

CNNE

CPRT

CPSH

CRMT

CVCO

CWST

DECK

DOCU

DXCM

EDPFY

ELVT

EPRT

FATE

Flaherty Crumrine/Claymore Preferred Securities

FJTSY

FLEX

FORTY

FTMNF

GLDLF

GLPI

GLVMF

HNNMY

INVH

ITCC

ITMR

KDDIY

LBRDA

LBRDK

LJUIF

LLIT

MCBI

MCRI

MDLZ

MGEE

MGRUF

Blackrock Muniholdings New York Quality Fund

MKTAY

MLKKF

MSCI

Blackrock Muniholdings California Quality Fund

NDAQ

Nuveen Insured Tax-Free Advantage Municipal Fund

Nuveenn Intermediate Duration Quality Municipal Term Fund Common Shares of Beneficial Interest

Nuveen Georgia Dividend Advantage Municipal Funds 2

Nuveen Insured California Tax-Free Advantage Municipal Fund

Nuveen Municipal High Income Opportunity Fund

Stocks That Hit 52-Week Highs On Friday

SSY Group Ltd

SSY Group (HK:2005) has released an update. SSY Group Limited has received approval from the National Medical Products Administration of China for ...

SSY Group Secures Key Drug Approvals in China

SSY Group (HK:2005) has released an update. SSY Group Limited has received approval from China's National Medical Products Administration for the p...

SSY Group Gains Approval for Key Drug in China

SSY Group (HK:2005) has released an update. SSY Group Limited has announced that China's National Medical Products Administration has approved the ...

SSY Group Gains Approval for Key Drug Development

SSY Group (HK:2005) has released an update. SSY Group has successfully included two of its drugs, Stiripentol Dry Suspension and Etomidate Medium/L...

SSY Group's Drugs Join China's Reimbursement List

SSY Group Gains Approval for Key Drug Production

SSY Group (HK:2005) has released an update. SSY Group has received approval from China's National Medical Products Administration for their Deferas...

SSY Group (HK:2005) has released an update. SSY Group Limited has secured approval from China's National Medical Products Administration for its dr...

SSY Group Gains Key Approvals for New Drugs

SSY Group (HK:2005) has released an update. SSY Group Limited has entered a strategic framework agreement with HighTide Therapeutics, Inc., focusin...

SSY Group Partners with HighTide for Innovative Health Solutions

SSY Group (HK:2005) has released an update. SSY Group has renewed its agreements with Sichuan Kelun for the sale and purchase of materials, as well...

SSY Group Renews Key Agreements with Sichuan Kelun

SSY Group (HK:2005) has released an update. SSY Group Limited has received approval from China's National Medical Products Administration for its F...

Comments

SSY Group

News

Latest news for SSY Group (OTC:LJUIF) Stock

Friday, January 31, 2020

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga